NCT04106856
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +12 more
- Locations
-
- Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
Clinical trial condition
Borderline Resectable Pancreatic Adenocarcinoma
Explore clinical trials studying Borderline Resectable Pancreatic Adenocarcinoma. Study availability and eligibility vary by location and protocol.
17 public trials
8 recruiting studies
Borderline Resectable Pancreatic Adenocarcinoma trial results
NCT03970252
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
- Locations
-
- UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
NCT02394535
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, +4 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
- MD Anderson in Katy Houston, Texas, United States
- MD Anderson Cancer Center - League City League City, Texas, United States
- MD Anderson in Sugar Land Sugar Land, Texas, United States
Active, Not Recruiting
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
NCT04484909
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +9 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
NCT04940286
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +11 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)
NCT04423731
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Chemotherapy Effect, Locally Advanced Pancreatic Adenocarcinoma, +1 more
- Locations
-
- Oslo University Hospital Oslo, Norway
Active, Not Recruiting
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
NCT02446093
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma
- Locations
-
- Lee Health/Regional Cancer Center Fort Myers, Florida, United States
- Ohio State University Columbus, Ohio, United States
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Mexico City, Mexico